Aktis Oncology (AKTS Proposed) started 2026 off with a sprint – becoming the first company to disclose IPO terms in 2026 – with an S-1/A filing early today – Monday, Jan. 5, 2026: The biotech is offering 11.78 million shares at a price range of $16.00 to $18.00 to raise $200 million. Bankers expect to price Aktis Oncology’s IPO this week. (Please see the IPO Calendar.) At pricing, Aktis Oncology would have a market cap of $793 million – if the IPO is priced at the $17.00 mid-point of its range.
J.P. Morgan, BofA Securities, Leerink Partners and TD Cowen are the joint book-runners.
The radiopharmaceutical biotech plans to use most of the IPO’s proceeds to fund two clinical trials of its leading drug candidate to treat patients with solid tumors, according to the prospectus.
(For more information about these companies, please check the IPO Calendar and the individual IPO Profiles found on the IPOScoop.com website.)
Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.
To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.
Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.
Disclaimer: A SCOOP Rating (Wall Street Consensus of Opening-day Premiums) is a general consensus taken, at press time, from Wall Street and investment professionals concerning how well an IPO might perform when it starts trading. The SCOOP Rating does not reflect the opinions of anyone associated with IPOScoop.com. The SCOOP ratings should not be taken as investment advice. The rating merely reflects the opinion of the professionals at the time of publication and the rating is subject to last-minute changes due to market conditions, changes in a specific offering and other factors, such as changes in the proposed offering terms and the shifting of investor interest in the IPO. The information offered is taken from sources we believe to be reliable, but we cannot guarantee the accuracy.